Mélissa Chénard - Concepedia

Concepedia

Author

Mélissa Chénard

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

M. Chénard, Melissa Chenard, Mélissa Chénard, Pierobon, Mariaelena

54

Publications

1.6K

Citations

16

H-Index

38

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)United States Military Academy

MC

About

Mélissa Chénard is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, drug discovery, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	14	1.3K
2	Biochemistry	9	9	424
3	Natural Sciences	8	8	404
4	Cell Biology	3	3	369
5	Cellular Physiology	1	1	16

Mélissa Chénard

×

17

Publications

1.6K

Citations

16

H-Index

	Year	Citations
An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies Jennifer O’Neil, Yair Benita, Igor Feldman, Molecular Cancer Therapeutics Drug TargetCombination Drug TherapyTumor BiologyOncologyCancer Cell Biology	2016	410
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression Tikvah K. Hayes, Nicole F. Neel, Chaoxin Hu, Cancer Cell OncologyPancreatic CancerLong-term Erk InhibitionMedicineSenescence-like Growth Suppression	2015	271
Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2) Joey L. Methot, Prasun K. Chakravarty, Mélissa Chénard, Bioorganic & Medicinal Chemistry Letters Histone ModificationsChromatinMedicinal ChemistrySelective Hdac1/hdac2 InhibitorsBiochemistry	2007	185
A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors Andrey Loboda, Michael Nebozhyn, Rich A. Klinghoffer, BMC Medical Genomics	2010	151
Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2) David J. Witter, Paul E. Harrington, Kevin J. Wilson, Bioorganic & Medicinal Chemistry Letters Biaryl Selective Hdac1Molecular PharmacologyMedicinal ChemistryMedicineRational Drug Design	2007	94
MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor Bo‐Sheng Pan, Grace K.Y. Chan, Mélissa Chénard, Cancer Research Activated C-met ReceptorCell CultureCancer BiologyTumor BiologyMolecular Pharmacology	2010	82
Functional role of the NPxxY motif in internalization of the type 2 vasopressin receptor in LLC-PK1 cells Richard Bouley, Tian‐Xiao Sun, Mélissa Chénard, American Journal of Physiology-Cell Physiology	2003	58
A Quantitative Volumetric Micro-Computed Tomography Method to Analyze Lung Tumors in Genetically Engineered Mouse Models Brian B. Haines, Kimberly A. Bettano, Mélissa Chénard, Neoplasia	2009	49
SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2) Joey L. Methot, Christopher L. Hamblett, Dawn M. Mampreian, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryPharmaceutical ScienceSar ProfilesBiochemistryMedicine	2008	44
The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors Christopher L. Hamblett, Joey L. Methot, Dawn M. Mampreian, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryBiochemistryMedicineNatural SciencesRational Drug Design	2007	43

Page 1